Agenus (NASDAQ:AGEN) Upgraded to Hold at StockNews.com

Agenus (NASDAQ:AGEN) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Friday.

Several other research firms have also commented on AGEN. Robert W. Baird reduced their target price on shares of Agenus from $6.00 to $3.00 and set a “neutral” rating on the stock in a report on Wednesday, March 12th. HC Wainwright reissued a “neutral” rating on shares of Agenus in a report on Tuesday. Six research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $8.75.

Agenus Stock Performance

Shares of AGEN stock traded down $0.06 on Friday, hitting $1.61. 733,912 shares of the company’s stock traded hands, compared to its average volume of 610,897. Agenus has a one year low of $1.61 and a one year high of $19.69. The company’s fifty day simple moving average is $3.01 and its 200 day simple moving average is $3.67. The stock has a market capitalization of $37.77 million, a price-to-earnings ratio of -0.14 and a beta of 1.23.

Agenus (NASDAQ:AGEN) last released its earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) EPS for the quarter, beating the consensus estimate of ($2.36) by $0.32. The business had revenue of $26.84 million for the quarter, compared to the consensus estimate of $30.09 million. As a group, sell-side analysts anticipate that Agenus will post -12.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Agenus

Several institutional investors and hedge funds have recently modified their holdings of the stock. Deutsche Bank AG lifted its position in shares of Agenus by 538.4% in the 4th quarter. Deutsche Bank AG now owns 61,144 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 51,566 shares during the period. Corton Capital Inc. purchased a new stake in shares of Agenus in the 4th quarter worth about $36,000. Bank of America Corp DE lifted its position in shares of Agenus by 34.0% in the 4th quarter. Bank of America Corp DE now owns 107,123 shares of the biotechnology company’s stock worth $294,000 after purchasing an additional 27,157 shares during the period. Jane Street Group LLC lifted its position in shares of Agenus by 97.6% in the 4th quarter. Jane Street Group LLC now owns 105,705 shares of the biotechnology company’s stock worth $290,000 after purchasing an additional 52,215 shares during the period. Finally, B. Riley Financial Inc. purchased a new stake in shares of Agenus in the 4th quarter worth about $2,074,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.